Low cerebrospinal fluid somatostatin in Parkinson disease

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Neurology

• Publication date

  1982-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.32.3.312PMID 6121303
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The origin of cerebrospinal fluid somatostatin: hypothalamic or disperse central nervous system secretion?

  1981cited by this paper
• Low somatostatin content in cerebrospinal fluid in multiple sclerosis

  1980cited by this paper
• Recent advances in research on Parkinsonism.

  1978cited by this paper
• Somatostatin in the treatment of patients with extrapyramidal disorders and patients with EEG abnormalities

  1978cited by this paper
• Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover.

  1978cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat.

  1976cited by this paper
• Immunohistochemical localization of somatostatin (growth hormone release-inhibiting factor) in the guinea pig brain.

  1974cited by this paper
• Measurement of and Correction for Incubation Damage in Radioimmunoassay

  1974cited by this paper
• Parkinson's disease: from brain homogenate to treatment.

  1973cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

  1973cited by this paper
• Wick Chromatography for Rapid and Reliable Immunoassay of Insulin, Glucagon and Growth Hormone

  1968cited by this paper
• Parkinsonism

  1967cited by this paper

• Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease.

  2025cites this paper
• Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit

  2024cites this paper
• Brain Proteome Profiling Reveals Common and Divergent Signatures in Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy

  2024cites this paper
• Sleep disorders cause Parkinson's disease or the reverse is true: Good GABA good night

  2024cites this paper
• Neuromolecular imaging in Parkinson's disease

  2020cites this paper
• Cyclosomatostatin-induced catalepsy in aged rats: Specific change of brain c-Fos protein expression in the lateral entorhinal cortex.

  2020cites this paper
• Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations

  2019cites this paper
• Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease

  2019cites this paper
• Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice

  2019cites this paper
• Decrease in somatostatin‐positive cell density in the amygdala of females with major depression

  2017cites this paper
• Histamine Potentiates Cyclosomatostatin-Induced Catalepsy in Old Rats

  2015cites this paper
• Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

  2014influential citation
• Somatostatin antagonist induces catalepsy in the aged rat

  2013cites this paper
• Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

  2013cites this paper
• Cerebrospinal fluid biomarkers for neurodegenerative disorders

  2013cites this paper
• Somatostatin and cognitive function in neurodegenerative disorders.

  2012cites this paper
• Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat.

  2012cites this paper
• Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach

  2010cites this paper
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cites this paper
• Cuantificación de eritropoyetina y somatostatina intravítrea: estudio comparativo entre pacientes con diabetes mellitus y trombosis venosa retiniana

  2008cites this paper
• Predator stress induces behavioral inhibition and amygdala somatostatin receptor 2 gene expression

  2008cites this paper
• Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease — effect of L-Dopa

  2005cites this paper
• Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat

  2004cites this paper
• Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus

  2004cites this paper
• Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease

  2004influential citation
• Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats.

  2002cites this paper
• Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy.

  2002cites this paper
• Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis.

  1999cites this paper
• Possible role of neuropeptides in obsessive compulsive disorder.

  1999cites this paper
• The organization and function of endogenous antinociceptive systems.

  1996cites this paper
• Brain Neuropeptidergic Function in Suicide Victims

  1996cites this paper
• CSF somatostatin increase in patients with early parkinsonian syndrome

  1995cites this paper
• Nimodipine Increases CSF Somatostatin in Affectively Ill Patients

  1995cites this paper
• Neuropeptide levels in discrete brain regions in the iminodipropionitrile-induced persistent dyskinesia rat model.

  1995cites this paper
• A long‐term follow‐up study of cerebrospinal fluid somatostatin in delirium

  1994cites this paper
• Cerebrospinal Fluid Levels of Neuropeptides, Cortisol, and Amino Acids in Patients with Epilepsy

  1993cites this paper
• Alterations in Neuropeptides in Aging and Disease

  1993cites this paper
• CHAPTER 9 – Neurohormones in Depression and Anxiety

  1993cites this paper
• Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

  1993cites this paper
• CSF somatostatin in obsessive-compulsive disorder.

  1993cites this paper
• Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide Y in rat brain.

  1993cites this paper
• Parkinson's disease and dementia: clinical and neurochemical correlations.

  1992cites this paper
• Changes of the Neuroendocrine System in Alzheimer-type Dementia

  1992cites this paper
• Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

  1992cites this paper
• The Neurotoxicity of Methylmercury in the Developing Nervous System

  1992cites this paper
• Dopa-responsive dystonia with depigmentation of the substantia nigra and formation of Lewy bodies.

  1992cites this paper
• Neuropeptides in cerebrospinal fluid in normal-pressure hydrocephalus and dementia.

  1991cites this paper
• Cerebrospinal Fluid Markers of Alzheimer's Disease

  1991cites this paper
• Somatostatin cerebrospinal fluid levels in dementia

  1991cites this paper
• Somatostatin‐like immunoreactivity in the CSF of patients with dementia associated with alcoholism

  1990cites this paper
• Cerebrospinal fluid somatostatin in delirium. II Changes at the acute stage and at one year follow-up

  1990cites this paper
• Ventricular fluid neuropeptides in Parkinson's disease. I. Levels and distribution of somatostatin-like immunoreactivity.

  1990cites this paper
• The effects of somatostatin and somatostatin antiserum on the retention of passive avoidance behavior after neofrontal decortication in rats.

  1990cites this paper
• Somatostatin-immunoreactive neurons in the rat striatum: effects of corticostriatal and nigrostriatal dopaminergic lesions.

  1990cites this paper
• CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.

  1990cites this paper
• Somatostatin‐Like Immunoreactivity in the Cerebrospinal Fluid of Aged Patients with Parkinson's Disease

  1990cites this paper
• SOMATOSTATIN AND SUBSTANCE P IN THE CEREBROSPINAL FLUID OF SOME NEURODEGENERATIVE DISORDERS

  1990cites this paper
• Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.

  1989cites this paper
• Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.

  1989cites this paper
• Neuropeptide modulation of central vestibular circuits.

  1989cites this paper
• Cerebrospinal fluid somatostatin in delirium

  1989cites this paper
• Elevated CSF somatostatin concentrations in demented patients parallel improved psychomotor functions induced by integrity‐promoting care

  1989cites this paper
• Somatostatin-like immunoreactivity and neurotransmitter metabolites in the cerebrospinal fluid of patients with senile dementia of Alzheimer type and Parkinson's disease

  1989cites this paper
• Neurotransmitter und Neuropeptide in den Basalganglien des Menschen

  1989cites this paper
• CSF somatostatin is elevated in patients with postzoster neuralgia

  1988cites this paper
• Methylmercury-induced movement and postural disorders in developing rat: loss of somatostatin-immunoreactive interneurons in the striatum.

  1988cites this paper
• Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness An overview

  1988cites this paper
• Somatostatin in neuropsychiatric disorders.

  1988cites this paper
• Neuroactive substances in cerebrospinal fluid. Normal and pathological regulatory mechanisms.

  1988cites this paper
• Dementia in Parkinson’s Disease

  1988cites this paper
• Zur Neurochemie der Huntingtonschen Krankheit

  1988cites this paper
• Recurrent Affective Disorders: Lessons from Limbic Kindling

  1988cites this paper
• The neurobiology of aging and the neurobiology of depression: is there a relationship?

  1988cites this paper
• Neuroactive Substances in Cerebrospinal Fluid

  1988cites this paper
• In situ hybridization: visualizing brain messenger RNA

  1988cites this paper
• CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects.

  1988cites this paper
• Endocrine changes in Alzheimer's disease.

  1988cites this paper
• Somatostatin and Depression

  1987cites this paper
• Somatostatin and Behavior: Preclinical and Clinical Studies

  1987cites this paper
• beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease.

  1987cites this paper
• The hypothalamus in Parkinson's disease.

  1987cites this paper
• β-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease

  1987cites this paper
• Chemical neurotransmission in the parkinsonian brain.

  1987cites this paper
• The hypothalamus in Parkinson Disease

  1987cites this paper
• CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects.

  1987cites this paper
• Lack of effect of chronic carbamazepine on brain somatostatin in the rat

  1987cites this paper
• Somatostatin im Liquor von Patienten mit Zosterneuralgie

  1987cites this paper
• Decreased somatostatin-like immunoreactivity in cerebral cortex and cerebrospinal fluid in Alzheimer's disease.

  1987cites this paper
• CSF somatostatin in multiple sclerosis

  1987cites this paper
• Neuropeptides and Parkinson's disease.

  1986cites this paper
• Neuropeptides and dementia.

  1986cites this paper
• Cerebrospinal fluid somatostatin and psychiatric illness.

  1986cites this paper
• Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type.

  1986cites this paper
• CSF cyclic nucleotides and somatostatin in Parkinson's disease

  1986cites this paper
• Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease.

  1986cites this paper
• Changes of frequency spectrum of the CSF pulse wave caused by supratentorial epidural brain compression.

  1986cites this paper
• CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients.

  1986cites this paper
• Non-pituitary actions of hypothalamic hormones. Functional significance and therapeutic implications. General introduction.

  1986cites this paper
• Somatostatin regulation of the CRF-ACTH-cortisol axis.

  1986cites this paper
• CSF somatostatin‐like immunoreactivity in dementia

  1986cites this paper